Dr. King is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1717 6th Ave S
Birmingham, AL 35233Phone+1 800-822-8816
Summary
- I am a physician scientist, board-certified in Neurology and Clinical Neurophysiology with a special clinical focus on neuromuscular disorders including ALS. At the basic science level, I have a long-term research interest in the RNA regulation of neuroinflammation and targeting it for therapeutic benefit in the treatment of acute and chronic neurological disorders including neuropathic pain, stroke, spinal cord injury, traumatic brain injury and chronic degenerative diseases like ALS. I also have an interest in the peripheral neuromuscular system in ALS and its role in disease pathology and as a potential source for biomarkers to track disease progression.
Education & Training
- Duke University HospitalResidency, Neurology, 1987 - 1989
- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Neurology, 1986 - 1986
- Case Western Reserve University/University Hospitals Cleveland Medical CenterInternship, Internal Medicine, 1985 - 1986
- Duke University School of MedicineClass of 1985
Certifications & Licensure
- AL State Medical License 1992 - 2024
- NC State Medical License 1988 - 1992
- OH State Medical License 1985 - 1992
- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Clinical Neurophysiology
Clinical Trials
- Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2013 Apr 01
Publications & Presentations
PubMed
- 96 citationsMast cells and neutrophils mediate peripheral motor pathway degeneration in ALSEmiliano Trias, Peter H. King, Ying Si, Yuri Kwon, Valentina Varela
JCI Insight. 2018-10-04 - 11 citationsWnt antagonist FRZB is a muscle biomarker of denervation atrophy in amyotrophic lateral sclerosis.Thaddaeus Kwan, Mohamed Kazamel, Kristina Thoenes, Ying Si, Nan Jiang
Scientific Reports. 2020-10-07 - 7 citationsA Nitroalkene Benzoic Acid Derivative Targets Reactive Microglia and Prolongs Survival in an Inherited Model of ALS via NF-κB InhibitionSofía Ibarburu, Mariángeles Kovacs, Valentina Varela, Jorge Rodriguez-Duarte, Mariana Ingold
Neurotherapeutics. 2021-01-01
Journal Articles
- Inhibition of the RNA Regulator HuR by SRI-42127 Attenuates Neuropathic Pain After Nerve Injury Through Suppression of Neuroinflammatory ResponsesSorge, R. E. Si, Y. Norian, L. A. Guha, A. Moore, G. E. Nabors, L. B. Filippova, N. Yang, X. Smith, R. Chellappan, R. King, P. H., Neurotherapeutics
Press Mentions
- King Earns Two Significant VA AwardsMay 12th, 2023
- UAB Researcher Receives Funding to Study Link Between Periodontitis and Alzheimer’s DiseaseAugust 16th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: